Delivery of atropine complexed with hydroxypropyl beta‐cyclodextrin via a contact lens
Optometry and Vision Science · 2026-11 · 103 (11)
DOI: 10.1002/ovs2.70115 ↗Abstract
ABSTRACT Purpose Myopia is a global vision problem linked to a significant economic burden and potential blindness in severe cases. Current interventions—including atropine eye drops, contact lenses, spectacles, and lifestyle changes—are often combined due to limited individual effectiveness. This study aimed to develop and stabilize atropine formulations, load them into contact lenses, and evaluate atropine release profiles. Methods Atropine sulfate was converted to atropine base and complexed with 2‐hydroxypropyl beta‐cyclodextrin (HPBCD) in phosphate‐buffered saline (PBS) at pH 6.5 or 7.4. Formulation stability was monitored over one year at room temperature (21°C) using high‐performance liquid chromatography (HPLC). Etafilcon A and omafilcon A lenses were soaked in the formulations for 24 hours. The amount of atropine base loaded and released was quantified via HPLC, and toxicity was assessed according to ISO 10993‐5. Results After 1 year, the formulations retained 97.3% (pH 6.5) and 80.3% (pH 7.4) of atropine base. At pH 6.5, etafilcon A and omafilcon A absorbed 3.2 ± 0.1 μg and 1.7 ± 0.6 μg of atropine base, respectively. Etafilcon A released 100% of the atropine base within 4 hours, and omafilcon A released 59% within 2 hours. Contact lens eluates showed no toxicity. Conclusions These findings support the stability and safety of atropine base formulations for potential ocular drug delivery.
EUVIMED